医薬品安全性市場：機能、デリバリーモード、エンドユーザー別-2025-2030年世界予測

医薬品安全性市場は、2023年に115億6,000万米ドルと評価され、2024年には140億6,000万米ドルに達すると予測され、CAGR 21.70％で成長し、2030年には457億4,000万米ドルに達すると予測されています。

医薬品安全性市場は製薬業界において重要な役割を担っており、医薬品の使用に伴うリスクを特定、評価、軽減することで、医薬品の安全性、有効性、品質を確保することに注力しています。医薬品安全性は、医薬品に関する世界的に厳しいガイドラインを考慮し、副作用を防止し、規制遵守を確実にするために必要です。適用範囲は前臨床試験から市販後調査に及び、エンドユーザーには製薬会社、規制当局、ヘルスケアプロバイダー、患者が含まれます。成長に影響を与える主な要因としては、慢性疾患の有病率の上昇、医薬品開発活動の活発化、規制要件の強化、ファーマコビジランスプロセスにおけるAIやビッグデータ解析などの先進技術の採用などが挙げられます。しかし、市場は安全性試験やコンプライアンスに関連する高コスト、複雑な規制状況、時間のかかる承認プロセスなどの制約に直面しています。現在のビジネスチャンスは、より個別化された医薬品安全性評価を必要とする個別化医療の拡大と、リアルタイムの安全性監視ソリューションの需要を促進する患者中心のアプローチの重視の高まりにあります。企業は、革新的な安全管理ソリューションや技術的進歩を活用するためのパートナーシップに投資することで、こうした機会を捉えることができます。さらに、ヘルスケア・インフラが急速に発展している新興国市場への進出は、有利な展望をもたらします。イノベーションと研究は、機械学習とAIを統合して安全性プロセスを合理化し、有害事象をより効率的に予測し、医薬品開発スケジュール全体を改善することに焦点を当てることができます。データプライバシーに関する懸念や国際的な規制の違いなどの課題はあるもの、市場は安全性プロトコルを強化する破壊的イノベーションの機が熟しています。監視の目と透明性への要求の高まりがこのダイナミックなセクターを形成し続ける中、一歩先を行くには、市場のリーダーシップと持続可能な成長を推進するために、技術統合と戦略的提携に熱心に取り組む必要があります。

市場力学：急速に進化する医薬品安全性市場の主要市場インサイトを公開

医薬品安全性市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響についてより明確に理解することができます。

• 市場促進要因
  • 喫煙人口の増加
  • 患者安全問題の深刻化
  • 企業によるアウトソーシングサービスの需要増加
• 市場抑制要因
  • 臨床試験に関する問題
• 市場機会
  • 研究開発活動の活発化
  • 新薬の上市を促進する医薬品安全性の採用増加
• 市場の課題
  • 医薬品の副作用

ポーターの5つの力：医薬品安全性市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：医薬品安全性市場における外部からの影響の把握

外部マクロ環境要因は、医薬品安全性市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析医薬品安全性市場における競合情勢の把握

医薬品安全性市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス医薬品安全性市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、医薬品安全性市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨医薬品安全性市場における成功への道筋を描く

医薬品安全性市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 喫煙中毒人口の増加
    • 患者の安全に関する問題の深刻化
    • プレーヤーによるアウトソーシングサービスの需要増加
  • 抑制要因
    • 臨床試験に関する問題
  • 機会
    • 研究開発活動の増加
    • 新薬の発売を促進する医薬品安全性の採用拡大
  • 課題
    • 薬の副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 医薬品安全性市場機能別

• ADRレポート
• 医薬品安全性監査
• 完全に統合されたソフトウェア
• 問題追跡

第7章 医薬品安全性市場配送方法別

• オンデマンド
• オンプレミス

第8章 医薬品安全性市場：エンドユーザー別

• ビジネスプロセスアウトソーシング
• 契約調査機関
• 製薬・バイオテクノロジー企業

第9章 南北アメリカの医薬品安全性市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の医薬品安全性市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの医薬品安全性市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AB CUBE S.A.S
• Accenture, plc
• ArisGlobal LLC
• Cinven
• Cognizant Technology Solutions Corp
• Ergomed PLC
• EXTEDO GmbH
• Genpact
• HCL Technologies Limited
• Indigene Pharmaceuticals, Inc.
• IQVIA Inc.
• Medco Health Solutions, Inc.
• Oracle Corporation
• Parexel International Corporation
• PPD Inc
• Sarjen Systems Pvt. Ltd
• Sparta Systems Inc.
• Syneos Health
• Worldwide Clinical Trials

LIST OF FIGURES

• FIGURE 1. DRUG SAFETY MARKET RESEARCH PROCESS
• FIGURE 2. DRUG SAFETY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DRUG SAFETY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DRUG SAFETY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DRUG SAFETY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DRUG SAFETY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DRUG SAFETY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DRUG SAFETY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DRUG SAFETY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DRUG SAFETY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DRUG SAFETY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DRUG SAFETY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DRUG SAFETY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUG SAFETY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUG SAFETY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DRUG SAFETY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DRUG SAFETY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DRUG SAFETY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DRUG SAFETY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRUG SAFETY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DRUG SAFETY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DRUG SAFETY MARKET DYNAMICS
• TABLE 7. GLOBAL DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DRUG SAFETY MARKET SIZE, BY ADR REPORTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DRUG SAFETY MARKET SIZE, BY DRUG SAFETY AUDITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DRUG SAFETY MARKET SIZE, BY FULLY INTEGRATED SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DRUG SAFETY MARKET SIZE, BY ISSUE TRACKING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DRUG SAFETY MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DRUG SAFETY MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DRUG SAFETY MARKET SIZE, BY BUSINESS PROCESS OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DRUG SAFETY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DRUG SAFETY MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS DRUG SAFETY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 30. CANADA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES DRUG SAFETY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC DRUG SAFETY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 47. CHINA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 50. INDIA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA DRUG SAFETY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 102. ITALY DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 114. POLAND DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 117. QATAR DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM DRUG SAFETY MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM DRUG SAFETY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM DRUG SAFETY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. DRUG SAFETY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. DRUG SAFETY MARKET, FPNV POSITIONING MATRIX, 2023

The Drug Safety Market was valued at USD 11.56 billion in 2023, expected to reach USD 14.06 billion in 2024, and is projected to grow at a CAGR of 21.70%, to USD 45.74 billion by 2030.

The drug safety market plays a critical role in the pharmaceutical industry, focused on ensuring the safety, efficacy, and quality of drugs by identifying, evaluating, and mitigating risks associated with their use. Drug safety is necessary to prevent adverse effects and ensure regulatory compliance, given the stringent guidelines worldwide for pharmaceuticals. The application scope ranges from pre-clinical trials to post-marketing surveillance, with end-users including pharmaceutical companies, regulatory authorities, healthcare providers, and patients. Key influencing growth factors include the rising prevalence of chronic diseases, increasing drug development activities, heightened regulatory requirements, and the adoption of advanced technologies such as AI and big data analytics in pharmacovigilance processes. However, the market faces limitations, including high costs associated with safety testing and compliance, complex regulatory landscapes, and time-consuming approval processes. Current opportunities lie in the expansion of personalized medicine, which requires more tailored drug safety evaluations, and the growing emphasis on patient-centric approaches that drive demand for real-time safety monitoring solutions. Companies can seize these opportunities by investing in innovative safety management solutions and partnerships to leverage technological advancements. Additionally, expanding into emerging markets, where healthcare infrastructure is rapidly developing, presents lucrative prospects. Innovation and research can focus on integrating machine learning and AI to streamline safety processes, predicting adverse outcomes more efficiently, and improving overall drug development timelines. Despite challenges, such as data privacy concerns and varying international regulations, the market is ripe for disruptive innovations that enhance safety protocols. As heightened scrutiny and transparency demands continue to shape this dynamic sector, staying ahead requires a keen focus on technological integration and strategic collaborations to drive market leadership and sustainable growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug Safety Market

The Drug Safety Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing population addicted to smoking
  • Escalating patient safety issues
  • Rise in demand for outsourcing services by players
• Market Restraints
  • Issues related to clinical trials
• Market Opportunities
  • Rising R&D activities
  • Increasing adoption of drug safety facilitating the launch of new drugs
• Market Challenges
  • Adverse effects of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Drug Safety Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug Safety Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug Safety Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug Safety Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug Safety Market

A detailed market share analysis in the Drug Safety Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug Safety Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug Safety Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug Safety Market

A strategic analysis of the Drug Safety Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug Safety Market, highlighting leading vendors and their innovative profiles. These include AB CUBE S.A.S, Accenture, plc, ArisGlobal LLC, Cinven, Cognizant Technology Solutions Corp, Ergomed PLC, EXTEDO GmbH, Genpact, HCL Technologies Limited, Indigene Pharmaceuticals, Inc., IQVIA Inc., Medco Health Solutions, Inc., Oracle Corporation, Parexel International Corporation, PPD Inc, Sarjen Systems Pvt. Ltd, Sparta Systems Inc., Syneos Health, and Worldwide Clinical Trials.

Market Segmentation & Coverage

This research report categorizes the Drug Safety Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Functionality, market is studied across ADR Reporting, Drug Safety Audits, Fully Integrated Software, and Issue Tracking.
• Based on Delivery Mode, market is studied across On-Demand and On-Premise.
• Based on End User, market is studied across Business Process Outsourcing, Contract Research Organizations, and Pharma & Biotech Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing population addicted to smoking
    • 5.1.1.2. Escalating patient safety issues
    • 5.1.1.3. Rise in demand for outsourcing services by players
  • 5.1.2. Restraints
    • 5.1.2.1. Issues related to clinical trials
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising R&D activities
    • 5.1.3.2. Increasing adoption of drug safety facilitating the launch of new drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects of drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Drug Safety Market, by Functionality

• 6.1. Introduction
• 6.2. ADR Reporting
• 6.3. Drug Safety Audits
• 6.4. Fully Integrated Software
• 6.5. Issue Tracking

7. Drug Safety Market, by Delivery Mode

• 7.1. Introduction
• 7.2. On-Demand
• 7.3. On-Premise

8. Drug Safety Market, by End User

• 8.1. Introduction
• 8.2. Business Process Outsourcing
• 8.3. Contract Research Organizations
• 8.4. Pharma & Biotech Companies

9. Americas Drug Safety Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Drug Safety Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Drug Safety Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AB CUBE S.A.S
• 2. Accenture, plc
• 3. ArisGlobal LLC
• 4. Cinven
• 5. Cognizant Technology Solutions Corp
• 6. Ergomed PLC
• 7. EXTEDO GmbH
• 8. Genpact
• 9. HCL Technologies Limited
• 10. Indigene Pharmaceuticals, Inc.
• 11. IQVIA Inc.
• 12. Medco Health Solutions, Inc.
• 13. Oracle Corporation
• 14. Parexel International Corporation
• 15. PPD Inc
• 16. Sarjen Systems Pvt. Ltd
• 17. Sparta Systems Inc.
• 18. Syneos Health
• 19. Worldwide Clinical Trials